Summary by Moomoo AI
On December 31, 2023, a Schedule 13G amendment was filed with the SEC by Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton, collectively referred to as the Reporting Persons, regarding their holdings in Panbela Therapeutics, Inc. The amendment indicates that the Reporting Persons no longer beneficially own more than five percent of Panbela Therapeutics' common stock, as they report owning 0 shares. Jeff Easton, as the managing member of Lind Global Partners II LLC and the general partner of Lind Global Fund II LP, is deemed to have sole voting and dispositive power over the shares previously held by Lind Global Fund II LP. The filing was certified by Jeff Easton on February 13, 2024, and includes a joint filing agreement among the Reporting Persons.